Novartis signs deal to boost cell therapy portfolio
ZURICH (Reuters) - Swiss drugmaker Novartis AG said on Friday it had signed a licensing and research deal that could boost its ability to develop innovative cell-based therapies for conditions where little treatment is currently available.
The maker of blockbuster blood pressure drug Diovan said it would use a stem-cell based platform developed by U.S.-based biopharmaceutical company Regenerex to help broaden its cell therapy portfolio.
Timothy Wright, head of development at Novartis Pharmaceuticals, said the agreement would support Novartis' leadership position in cell therapy.
- U.S. man sues soccer star Cristiano Ronaldo over CR7 trademark
- Wall Street drops, S&P on track for worst day since April
- Sierra Leone declares emergency as Ebola death toll hits 729 |
- Moscow fights back after sanctions; battle rages near Ukraine crash site |
- Netanyahu vows to complete Gaza tunnels destruction |